Regentis Biomaterials Ltd. (NYSE American: RGNT) is positioning its Gelrin C hydrogel as a practical regenerative medicine solution for cartilage damage, aiming to address the substantial clinical and economic burden associated with knee osteoarthritis (OA). The company announced that Gelrin C is a cell-free, off-the-shelf hydrogel administered in a single 10-minute procedure, designed to support cartilage regeneration while avoiding the multiple surgeries, specialized laboratory processing and higher costs associated with some cell-based therapies.
According to the company, approximately 470,000 knee cartilage repair procedures are performed annually in the U.S., representing an estimated $3 billion market. Regentis believes Gelrin C could offer a more scalable approach that fits existing surgical workflows and addresses cartilage defects before they progress to costly OA. The economic impact of knee OA is significant, with estimates suggesting the annual U.S. economic burden ranges from approximately $5.7 billion to $15 billion, and lifetime costs for affected patients potentially exceeding $140,000.
As Regentis advances Gelrin C toward commercialization, its single-stage design, proprietary hydrogel technology and clinical data could position the company to benefit from growing demand for regenerative treatments that preserve joint health and potentially delay or prevent more expensive degenerative disease. The product is designed to be eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process.
Regentis Biomaterials is a regenerative medicine company focused on developing innovative tissue repair solutions. With an initial focus on orthopedic treatments, the company’s Gelrin platform technology uses synchronized, degradable hydrogel implants to regenerate damaged or diseased tissue, including inflamed cartilage and bone. The company notes that Gelrin C aims to address a market where no off-the-shelf treatment is currently available.
For more information, visit the company’s newsroom at https://ibn.fm/RGNT.
